Cancer immunotherapy has had a tremendous impact on a wide range of cancers, including B-cell lymphomas. However, it has not yet been effective in those lymphomas that originate primarily from T cells. The scientific challenge is in finding a therapy that can attack the cancerous T cells while leaving normal cells intact.
The SU2C Meg Vosburg T-cell Lymphoma Dream Team is testing engineered cells that carry molecules known as chimeric antigen receptors, or CARs, which can lock onto proteins on the surface of cancerous T cells and destroy them. Finding the best combination of CARs and engineered cell types is a key goal of the Dream Team.
CAR therapy is usually custom-built for each patient. The team is trying to find a way to develop CAR cells on an “off-the-shelf” basis so the therapy will be more available to patients and less expensive.
This team in named in honor of Mary Margaret (Meg) Moretti Vosburg, a lifelong learner, educator and humanitarian, who died May 26, 2018, after a hard-fought battle with lymphoma at the age of 51.